Abbott Laboratories (ABT) is a publicly traded Healthcare sector company. As of May 20, 2026, ABT trades at $88.23 with a market cap of $153.12B and a P/E ratio of 24.68. ABT moved -0.53% today. Year to date, ABT is -28.48%; over the trailing twelve months it is -34.47%. Its 52-week range spans $81.97 to $141.23. Analyst consensus is strong buy with an average price target of $120.24. Rallies surfaces ABT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ABT financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. ABT recently traded at $88.23. Market cap is $153.12B. P/E ratio is 24.68. Revenue is $45.13B.
| Metric | Value |
|---|---|
| Price | $88.23 |
| Market Cap | $153.12B |
| P/E Ratio | 24.68 |
| EPS | $3.59 |
| Dividend Yield | 0.63% |
| 52-Week High | $141.23 |
| 52-Week Low | $81.97 |
| Volume | 5.95M |
| Avg Volume | 0 |
| Revenue (TTM) | $45.13B |
| Net Income | $6.28B |
| Gross Margin | 56.26% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $44.33B | $6.52B | $3.73 |
| 2024 | $41.95B | $13.40B | $7.67 |
| 2023 | $40.11B | $5.72B | $3.28 |
| 2022 | $43.65B | $6.93B | $3.94 |
20 analysts cover ABT: 0 strong buy, 16 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $120.24.